Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease

Journal of Vascular Surgery

Volumn 62, Issue 1, 2015, Pages 157-165.e1

  Armstrong, Ehrin J ^a   Anderson, David R ^b   Yeo, Khung Keong ^b   Singh, Gagan D ^b   Bang, Heejung ^b   Amsterdam, Ezra A ^b   Freischlag, Julie A ^c   Laird, John R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLAUDICATION; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CRITICAL LIMB ISCHEMIA; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TOBACCO USE; TREATMENT RESPONSE; ADULT; AMPUTATION; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPLICATION; CRITICAL ILLNESS; DRUG COMBINATION; HOSPITAL INFORMATION SYSTEM; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; ASPIRIN; CALIFORNIA; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937524868     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2015.01.051     Document Type: Article

References (41)

1. M.H. Criqui, R.D. Langer, A. Fronek, H.S. Feigelson, M.R. Klauber, T.J. McCann, and et al. Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 1992 381 386
2. M.H. Criqui, J.K. Ninomiya, D.L. Wingard, M. Ji, and A. Fronek Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality J Am Coll Cardiol 52 2008 1736 1742
3. G.M. Welten, O. Schouten, S.E. Hoeks, M. Chonchol, R. Vidakovic, R.T. van Domburg, and et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease J Am Coll Cardiol 51 2008 1588 1596
4. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions J Vasc Surg 45 2007 645 654
5. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
6. T. Jonason, and R. Bergström Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality Acta Med Scand 221 1987 253 260
7. R.L. Pande, T.S. Perlstein, J.A. Beckman, and M.A. Creager Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004 Circulation 124 2011 17 23
8. H.H. Feringa, V.H. van Waning, J.J. Bax, A. Elhendy, E. Boersma, O. Schouten, and et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease J Am Coll Cardiol 47 2006 1182 1187
9. D.J. Kumbhani, P.G. Steg, C.P. Cannon, K.A. Eagle, S.C. Smith, S. Goto, and et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry Eur Heart J 35 2014 2864 2872
10. G.G. Westin, E.J. Armstrong, H. Bang, K.K. Yeo, D. Anderson, D.L. Dawson, and et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia J Am Coll Cardiol 63 2014 682 690
11. M. Catalano, G. Born, and R. Peto Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial J Intern Med 261 2007 276 284
12. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
13. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet 348 1996 1329 1339
14. D.L. Bhatt, K.A. Fox, W. Hacke, P.B. Berger, H.R. Black, W.E. Boden, and et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
15. P.P. Cacoub, D.L. Bhatt, P.G. Steg, E.J. Topol, M.A. Creager, and M.A. Creager Patients with peripheral arterial disease in the CHARISMA trial Eur Heart J 30 2009 192 201
16. C.E. McCoach, E.J. Armstrong, S. Singh, U. Javed, D. Anderson, K.K. Yeo, and et al. Gender-related variation in the clinical presentation and outcomes of critical limb ischemia Vasc Med 18 2013 19 26
17. M.E. Hill, and I. Rosenwaike The Social Security Administration's Death Master File: the completeness of death reporting at older ages Soc Secur Bull 64 2001 45 51
18. M.S. Conte, P.J. Geraghty, A.W. Bradbury, N.D. Hevelone, S.R. Lipsitz, G.L. Moneta, and et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia J Vasc Surg 50 2009 1462 1473 e1-3
19. R.B. Rutherford, J. Baker, C. Ernst, K. Johnston, J.M. Porter, S. Ahn, and et al. Recommended standards for reports dealing with lower extremity ischemia: revised version J Vasc Surg 26 1997 517 538
20. W.H. Chen, P.Y. Lee, W. Ng, H.F. Tse, and C.P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 2004 1122 1126
21. S. Spiliopoulos, G. Pastromas, K. Katsanos, P. Kitrou, D. Karnabatidis, and D. Siablis Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP Study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity J Am Coll Cardiol 61 2013 2428 2434
22. L.H. Curtis, B.G. Hammill, E.L. Eisenstein, J.M. Kramer, and K.J. Anstrom Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases Med Care 45 2007 S103 S107
23. J.M. Robins, M.A. Hernán, and B. Brumback Marginal structural models and causal inference in epidemiology Epidemiology 11 2000 550 560
24. S.R. Cole, and M.A. Hernán Adjusted survival curves with inverse probability weights Comput Methods Programs Biomed 75 2004 45 49
25. U.U. Dafni Landmark analysis at the 25-year landmark point Circ Cardiovasc Qual Outcomes 4 2011 363 371
26. F.G. Fowkes, J.F. Price, M.C. Stewart, I. Butcher, G.C. Leng, A.C. Pell, and et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
27. J. Belch, A. MacCuish, I. Campbell, S. Cobbe, R. Taylor, R. Prescott, and et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
28. 2011 Writing Group Members, 2005 Writing Committee Members, ACCF/AHA Task Force Members 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 124 2011 2020 2045
29. J.J. Belch, and J. Dormandy Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial J Vasc Surg 52 2010 825 828.e2
30. P.F. Wong, L.Y. Chong, D.P. Mikhailidis, P. Robless, and G. Stansby Antiplatelet agents for intermittent claudication Cochrane Database Syst Rev 2011 CD001272
31. M.P. Bonaca, B.M. Scirica, M.A. Creager, J. Olin, H. Bounameaux, M. Dellborg, and et al. Vorapaxar in patients with peripheral artery disease: results from TRA20P-TIMI 50 Circulation 127 2013 1522 1526
32. L. Martorell, J. Martínez-González, C. Rodríguez, M. Gentile, O. Calvayrac, and L. Badimon Thrombin and protease-activated receptors (PARs) in atherothrombosis Thromb Haemost 99 2008 305 315
33. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
34. K.P. Bliden, J. DiChiara, U.S. Tantry, A.K. Bassi, S.K. Chaganti, and P.A. Gurbel Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
35. D.J. Angiolillo, J.L. Ferreiro, M.J. Price, A.J. Kirtane, G.W. Stone, D.J. Angiolillo, and et al. Platelet function and genetic testing J Am Coll Cardiol 62 2013 S21 31
36. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, and et al. Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
37. G. Tepe, R. Bantleon, K. Brechtel, J. Schmehl, T. Zeller, C. Claussen, and et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy - the MIRROR study: a randomised and double-blinded clinical trial Eur Radiol 22 2012 1998 2006
38. J.P. Collet, T. Cuisset, G. Rangé, G. Cayla, S. Elhadad, C. Pouillot, and et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
39. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs, and et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
40. D. Karnabatidis, S. Spiliopoulos, G. Pastromas, P. Kitrou, N. Christeas, K. Katsanos, and et al. Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing Cardiovasc Intervent Radiol 37 2014 631 638
41. E. Faglia, G. Clerici, J. Clerissi, L. Gabrielli, S. Losa, M. Mantero, and et al. Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study Diabetes Care 32 2009 822 827